Combination Therapy of AIDS

Erik De Clercq, Anne-Mieke Vandamme (Herausgeber)

Buch | Softcover

XI, 243 Seiten

2012
Springer Basel (Verlag)
978-3-0348-9604-7 (ISBN)

Artikel merken

HIV infection has been a greater challenge to current medicine than any other viral disease ofmodem times. HIV leads to a persistent infection and the virus has an immense genetic flexibility under selective pressure. During its replica tive cycle in patients, HIV accumulates mutations at such a high rate that the selective pressure inflicted on the immune system, or generated by antiviral drugs rapidly triggers the appearance of escape mutants. Currently available drugs, when used singly, are not capable of suppressing virus replication in patients to such a level that the generation of mutations, from which a variant resistant to immune attack or antiviral drugs can be selected, is prevented. This is the main reason why combination therapy, usually of three drugs, has become the standard procedure for the treatment ofAIDS. It is obvious that virus eradication will not readily be achievable, so that drugs have to be taken for a prolonged time or even lifelong so as to keep the viral load as low as possible. Whether the currently used drug combinations will be able to control virus replication in a particular patient for such a pro longed period of time depends on many factors, most of which are addressed in the different chapters of this book. The aim of antiviral drug combination therapy for AIDS is ultimately to restore full function of the immune system.

Erik De Clercq, M.D., PhD is currently President of the Rega Foundation, a member of the Belgian (Flemish) Royal Academy of Medicine and of the Academia Europaea, and a Fellow of the American Association for the Advancement of Science. He is an active Emeritus Professor of the Katholieke Universiteit Leuven (K.U.Leuven), Belgium. He is honorary doctor of the Universities of Ghent, Belgium, Athens, Greece, Ferrara, Italy, Jinan (Shandong), China, Charles (Prague), Czech Republic, and Jihoceska (Bude?jovice), Czech Republic. For his pioneering efforts in antiviral research, Professor De Clercq received in 1996 the Aventis award from the American Society for Microbiology, and in 2000 the Maisin Prize for Biomedical Sciences from the Belgian National Science Foundation. In 2008 he was elected Inventor of the Year by the European Union. Together with Dr. Anthony Fauci, Prof. De Clercq received the Dr. Paul Janssen Award for Biomedical Research in 2010. He is the (co)inventor of a number of antiviral drugs, used for the treatment of HSV (valaciclovir, Valtrex , Zelitrex ), VZV (brivudin, Zostex , Brivirac , Zerpex ), CMV (cidofovir, Vistide ), HBV (adefovir dipivoxil, Hepsera ), and HIV infections (AIDS) (tenofovir disoproxil fumarate, Viread ).

Anti-HIV agents to be used in drug combination regimens.- A perspective of the history of HAART.- The basic principles for combination therapy.- Comparison of the efficacy of HAART: single, dual or triple-class antiretroviral therapy.- Pharmacokinetics and pharmacodynamics of HAART.- Primary HIV infection: from diagnosis to treatment.- Salvage therapy.- Structured therapy interruptions (STIs): lessons from a therapeutic strategy.- Immune reconstitution in HIV infection.- Highly active antiretroviral treatment (HAART) of pediatric HIV-1 infection.- Causes of HIV treatment failure.- Economic implication of HIV-1 resistance testing in overall clinical care.- Guidelines for antiretroviral therapy.- Visions for the future of antiretroviral therapy.

Erscheint lt. Verlag	23.10.2012
Reihe/Serie	Milestones in Drug Therapy
Zusatzinfo	XI, 243 p.
Verlagsort	Basel
Sprache	englisch
Maße	155 x 235 mm
Gewicht	398 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
Themenwelt	Medizin / Pharmazie ► Pharmazie
Schlagworte	AIDS • Assessment • Diagnosis • Drug • HIV • HIV Infection • immunology • Infection • Infectious Diseases • Pharmacodynamics • Pharmacokinetics • pharmacology • Public Health • Research • resistance • therapy
ISBN-10	3-0348-9604-2 / 3034896042
ISBN-13	978-3-0348-9604-7 / 9783034896047
Zustand	Neuware